Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093145 · ClinicalTrials.gov registry record · Phase 2
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00093145 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 32 participants.
The verdict
NCT00093145, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.
Interventions
- DRUG Carboplatin
- DRUG Albumin-bound paclitaxel
- DRUG Herceptin®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-06-01 |
| Est. Completion | 2008-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093145
The ClinicalTrials.gov registry entry for NCT00093145 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00093145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093145 about?
NCT00093145 is a clinical study titled "Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer". This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may contin...
What is the current status of trial NCT00093145?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2004-06-01. Estimated completion is 2008-10-01.
What interventions are being tested in trial NCT00093145?
The interventions under investigation include: Carboplatin (DRUG), Albumin-bound paclitaxel (DRUG), Herceptin® (DRUG).
Who is sponsoring clinical trial NCT00093145?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.